Harmony Biosciences Holdings, Inc. Common Stock (HRMY) is a publicly traded Healthcare sector company. As of May 21, 2026, HRMY trades at $32.75 with a market cap of $1.73B and a P/E ratio of 12.41. HRMY moved +3.09% today. Year to date, HRMY is -14.61%; over the trailing twelve months it is -11.90%. Its 52-week range spans $25.52 to $41.61. Analyst consensus is buy with an average price target of $43.44. Rallies surfaces HRMY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Harmony Biosciences Raises 2026 Revenue Estimate to $1.02B, Cuts EPS to $3.58: Harmony Biosciences will report Q1 2026 results May 7 with expected revenue of $227.27 million and earnings of $0.75 per share. Analysts raised full-year 2026 revenue forecast to $1.02 billion from $1.00 billion while cutting EPS to $3.58 and Q4 revenue beat by 1.41% but EPS slumped 54.55%.
| Metric | Value |
|---|---|
| Price | $32.75 |
| Market Cap | $1.73B |
| P/E Ratio | 12.41 |
| EPS | $2.53 |
| Dividend Yield | 0.00% |
| 52-Week High | $41.61 |
| 52-Week Low | $25.52 |
| Volume | 19 |
| Avg Volume | 0 |
| Revenue (TTM) | $899.11M |
| Net Income | $145.62M |
| Gross Margin | 76.55% |
9 analysts cover HRMY: 0 strong buy, 5 buy, 3 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $43.44.